|
|
|
We recap Day 2 of the 2025 BIO CEO and Investor Conference in New York with a look at what we can expect from the new administration and Congress, as well as promising schizophrenia developments. (347 words, 1 minute, 44 seconds)
|
|
|
|
How to catch up on the BIO CEO & Investor Conference |
|
|
The BIO CEO & Investor Conference wrapped up in New York yesterday—here’s how you can follow our coverage: - Read the Bio.News newsletter and website for panel recaps, videos, and much more.
- Join the conversation on X with #BIOCEO25.
|
|
|
|
|
Challenges and opportunities in the new administration |
|
|
|
On Day 2 of the BIO CEO and Investor Conference in New York, panelists discussed challenges and opportunities ahead in the new administration and Congress. The panel: “Policy Outlook: Navigating a New Congress and Executive Branch,” The takeaway: It’s hard to be sure what will happen, but efforts to streamline regulation could help biotech. Meanwhile, Medicaid reform could push the price control battle to the states, where patients would be good allies in the fight.
What they’re saying: “The pace is just different. You know, this is not federal government as usual,” said Remy Brim, Principal, Health Care Practice Head, BGR Government Affairs, LLC. “I think we just need to get used to that pace and not get distracted and continue to look at what our long-term objectives are.” Read more on Bio.News. |
|
|
New solution for the challenge of schizophrenia |
|
|
|
Roughly 1% of the world population has schizophrenia, but until recently, treatment options were limited.
The panel: “Policy Outlook: Navigating a New Congress and Executive Branch.”
The takeaway: Drugs for schizophrenia have targeted dopamine receptors, but that approach did not address all of the symptoms. And side effects meant patients would often stop taking these drugs. But the approved Cobenfy, which has a different target, is promising.
What they’re saying: “We’ve always been treating schizophrenia as too much dopamine, and so we’ve been trying to improve the symptoms of it by pressing downward on it, by blocking those receptors,” said Ken Kramer, VP and Head of Medical Affairs, Neuropsychiatry at BMS. “But there’s another way to do it. You can lift the other side.” Read more on Bio.News. |
|
|
|
|
|
|
|
|
|
